Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. SPRB, AFMD, GRAY, PTN, VCNX, GRTX, ONCT, BPTH, OGEN, and ASLNShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Spruce Biosciences (SPRB), Affimed (AFMD), Graybug Vision (GRAY), Palatin Technologies (PTN), Vaccinex (VCNX), Galera Therapeutics (GRTX), Oncternal Therapeutics (ONCT), Bio-Path (BPTH), Oragenics (OGEN), and ASLAN Pharmaceuticals (ASLN). Athersys vs. Its Competitors Spruce Biosciences Affimed Graybug Vision Palatin Technologies Vaccinex Galera Therapeutics Oncternal Therapeutics Bio-Path Oragenics ASLAN Pharmaceuticals Spruce Biosciences (NASDAQ:SPRB) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Is SPRB or ATHX more profitable? Athersys has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Athersys' return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Athersys N/A N/A -223.03% Do institutionals & insiders believe in SPRB or ATHX? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by company insiders. Comparatively, 0.0% of Athersys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, SPRB or ATHX? Spruce Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Do analysts prefer SPRB or ATHX? Spruce Biosciences currently has a consensus price target of $1.75, indicating a potential upside of 1,490.91%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Athersys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, SPRB or ATHX? Spruce Biosciences has higher revenue and earnings than Athersys. Spruce Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.95-$47.92M-$1.32-0.08Athersys$146K0.00-$72.53M-$2.03N/A Does the media prefer SPRB or ATHX? In the previous week, Spruce Biosciences' average media sentiment score of 0.00 equaled Athersys'average media sentiment score. Company Overall Sentiment Spruce Biosciences Neutral Athersys Neutral SummarySpruce Biosciences beats Athersys on 9 of the 12 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833K$817.60M$5.55B$9.40BDividend YieldN/A4.84%3.75%4.03%P/E Ratio0.001.4128.0119.82Price / SalesN/A27.13432.8198.20Price / CashN/A19.5636.1658.27Price / BookN/A6.878.125.65Net Income-$72.53M-$4.17M$3.25B$257.91M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024SPRBSpruce Biosciences2.4697 of 5 stars$0.07-3.3%$1.75+2,400.0%-79.9%$2.96M$4.91M-0.0720Gap UpAFMDAffimed3.0319 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.7%$2.92M$877K0.00200Gap DownHigh Trading VolumeGRAYGraybug VisionN/A$1.61+1.9%N/A-39.6%$2.53MN/A-0.9327High Trading VolumePTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeVCNXVaccinex0.8361 of 5 stars$0.80+14.4%N/A-88.2%$2.08M$388K-0.0240GRTXGalera TherapeuticsN/A$0.03-11.6%N/A-80.9%$1.96MN/A-0.0730Gap DownONCTOncternal Therapeutics1.5227 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530BPTHBio-Path0.8257 of 5 stars$0.16-6.0%N/A-91.5%$1.33MN/A0.0010Gap DownOGENOragenics0.0606 of 5 stars$1.54+0.7%N/A-95.6%$1.27MN/A-0.225High Trading VolumeASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330 Related Companies and Tools Related Companies Spruce Biosciences Competitors Affimed Competitors Graybug Vision Competitors Palatin Technologies Competitors Vaccinex Competitors Galera Therapeutics Competitors Oncternal Therapeutics Competitors Bio-Path Competitors Oragenics Competitors ASLAN Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHX Stock Alerts